Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea · Delayed Price · Currency is KRW 5,710.00
-160.00 (-2.73%)
At close: Dec 5, 2025
Hyundai Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -21,965 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade |
Depreciation & Amortization | 1,156 | 633.82 | 1,435 | 1,782 | 2,703 | 3,778 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | 4,769 | - | 7,517 | 2,829 | Upgrade |
Loss (Gain) From Sale of Investments | 168.81 | -14.05 | -123.67 | -910.99 | - | - | Upgrade |
Loss (Gain) on Equity Investments | 4,213 | 5,730 | - | -8,834 | -93.91 | -1,542 | Upgrade |
Stock-Based Compensation | 40.49 | -77.98 | 402.42 | 596.94 | 578.26 | 1,032 | Upgrade |
Provision & Write-off of Bad Debts | -33.5 | 156.13 | -28.78 | 5,260 | -583.99 | -212.84 | Upgrade |
Other Operating Activities | 2,303 | 2,579 | 911.44 | -79.49 | 3,925 | 2,170 | Upgrade |
Change in Accounts Receivable | 36.49 | 43.52 | 864.23 | 1,184 | 3,526 | 4,585 | Upgrade |
Change in Inventory | -1,754 | 1,512 | 358.12 | 403.6 | 864.9 | 1,865 | Upgrade |
Change in Accounts Payable | 1,096 | 447.9 | -256.2 | 503.57 | 13.43 | 1,355 | Upgrade |
Change in Other Net Operating Assets | -751.94 | -1,824 | 159.77 | -642.06 | 1,063 | -97.7 | Upgrade |
Operating Cash Flow | -15,490 | 2,257 | -6,008 | -16,544 | -538.48 | 7,502 | Upgrade |
Operating Cash Flow Growth | - | - | - | - | - | -18.27% | Upgrade |
Capital Expenditures | -19,921 | -169.57 | -539.7 | -1,544 | -3,747 | -25,204 | Upgrade |
Sale (Purchase) of Intangibles | 26,934 | -2,000 | -47.84 | - | -15.12 | - | Upgrade |
Investment in Securities | -50,947 | -16,934 | 6,000 | 10,210 | -13,010 | 941.66 | Upgrade |
Other Investing Activities | 122.17 | -773.14 | -557 | -0.4 | 1,773 | 2.43 | Upgrade |
Investing Cash Flow | -43,218 | -19,740 | 5,177 | 8,518 | -12,359 | -26,831 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 2,000 | Upgrade |
Long-Term Debt Issued | - | 20,001 | - | - | - | 33,000 | Upgrade |
Total Debt Issued | - | 20,001 | - | - | - | 35,000 | Upgrade |
Short-Term Debt Repaid | - | -400 | -500 | -500 | - | - | Upgrade |
Long-Term Debt Repaid | - | -116.58 | -362.88 | -1,194 | -1,246 | -1,182 | Upgrade |
Total Debt Repaid | -24,308 | -516.58 | -862.88 | -1,694 | -1,246 | -1,182 | Upgrade |
Net Debt Issued (Repaid) | -24,308 | 19,484 | -862.88 | -1,694 | -1,246 | 33,818 | Upgrade |
Issuance of Common Stock | 84,258 | 139.96 | 1,094 | 3,596 | 4,449 | - | Upgrade |
Other Financing Activities | -476.66 | -434.78 | -289.18 | -229.04 | -209.66 | -867.11 | Upgrade |
Financing Cash Flow | 59,474 | 19,190 | -57.97 | 1,673 | 2,994 | 32,951 | Upgrade |
Foreign Exchange Rate Adjustments | 37.65 | 138.47 | -31.72 | -103.42 | -122.29 | 37.95 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | 0 | - | - | - | -0 | Upgrade |
Net Cash Flow | 803.99 | 1,845 | -920.54 | -6,456 | -10,026 | 13,660 | Upgrade |
Free Cash Flow | -35,411 | 2,087 | -6,548 | -18,087 | -4,285 | -17,702 | Upgrade |
Free Cash Flow Margin | -1806.42% | 13.87% | -69.06% | -230.36% | -46.37% | -141.49% | Upgrade |
Free Cash Flow Per Share | -295.50 | 26.21 | -82.31 | -229.72 | -58.04 | -246.46 | Upgrade |
Cash Interest Paid | 476.66 | 434.78 | 289.18 | 222.4 | 209.66 | 259.11 | Upgrade |
Cash Income Tax Paid | 100.39 | -54.28 | 19.19 | -17.99 | 78.92 | -15.64 | Upgrade |
Levered Free Cash Flow | -4,913 | -2,607 | -4,900 | -8,388 | 1,337 | -21,504 | Upgrade |
Unlevered Free Cash Flow | -3,113 | -1,162 | -4,704 | -8,108 | 3,214 | -20,797 | Upgrade |
Change in Working Capital | -1,373 | 180.01 | 1,126 | 1,449 | 5,467 | 7,708 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.